Johnson & Johnson MedTech’s Shockwave Medical has launched its Javelin Peripheral IVL Catheter in the US for peripheral artery disease (PAD).
This new intravascular lithotripsy (IVL) platform is engineered to modify calcium and navigate “extremely” narrowed vessels in individuals with this disease.
Go deeper with GlobalData
People with PAD are said to have an elevated heart attack or stroke risk.
The catheter has a 150cm working length and a distal emitter that generates up to 120 shockwave pulses, each generating a spherical energy field that spreads beyond the catheter’s tip.
This forward IVL platform is tailored for crossing calcified occlusive conditions or narrowed lesions that allow wire passage but impede device movement, stated the company.
Clinical findings from the FORWARD PAD investigational device exemption (IDE) trial showed that Shockwave Javelin has an effectiveness and safety profile comparable to existing balloon-based IVL catheters.
Its addition to Shockwave’s IVL portfolio, which includes Shockwave E8, L6, M5+, and S4 IVL catheters, claims to provide physicians with a full suite of tools for treating calcified lesions above and below the knee.
The company’s IVL technology is focused on treating atherosclerotic cardiovascular conditions by leveraging sonic pressure waves to “disrupt” calcified plaque.
Shockwave Medical chief medical officer Nick West said: “By listening to and leveraging their valuable insights, we developed our transformational forward IVL platform with the unique capability to both modify calcium and cross extremely narrowed vessels.
“We are proud to be leading the charge in offering endovascular interventionalists more flexibility to address critical treatment needs and potentially reduce the risks associated with chronic limb-threatening ischemia for their patients.”
In May 2024, Johnson & Johnson completed the acquisition of Shockwave Medical.
